News
Novo Nordisk announces CEO transition as share price slips
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release announcing the leadership shake up. Jorgensen will stay on as CEO temporarily for an undetermined period of time “to support a smooth transition” as the company looks for his replacement.
Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.
It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...
Novo Nordisk, the company that makes Wegovy and Ozempic, is abruptly ousting its chief executive over concerns the firm is losing ground in the popular weight-loss drug market. The firm's market value ...
Novo Nordisk said it's going to reduce spending to make up for the sales shortfall. On a conference call with analysts, Novo Nordisk executives were quizzed about the threat from compounding ...
Good day, and thank you for standing by. Welcome to the Q1 2025 Novo Nordisk A/S Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded.
Novo Nordisk is making yet another bet on obesity ... 4 months after going public Talking at the J.P. Morgan Healthcare Conference in January, Septerna CEO Jeffrey Finer, M.D., Ph.D., said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback